Back

SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time

Vaisman-Mentesh, A.; Dror, Y.; Tur-Kaspa, R.; Markovitch, D.; Kournos, T.; Dicker, D.; Wine, Y.

2020-08-25 infectious diseases
10.1101/2020.08.23.20179796
Show abstract

The breadth of the humoral immune response following SARS-CoV-2 infection was indicated to be important for recovery from COVID-19. Recent studies have provided valuable insights regarding the dynamics of the antibody response in symptomatic COVID-19 patients. However, the information regarding the dynamics of the serological and cellular memory in COVID-19 recovered patients in scarce. It is imperative to determine the persistence of humoral memory in COVID-19 recovered patients as it will help to evaluate the susceptibility of recovered patients to re-infection. Here, we describe the dynamics of both the SARS-CoV-2 specific serological and B cell response in COVID-19 recovered patients. We found that symptomatic SARS-CoV-2 patients mount a robust antibody response following infection however, the serological memory decays in recovered patients over the period of 6 months. On the other hand, the B cell response as observed in the SARS-CoV-2 specific memory B cell compartment, was found to be stable over time. Moreover, the frequency of SARS-CoV-2 specific B cell plasmablasts was found to be associated with the SARS-CoV-2 specific antibody levels. These data, suggests that the differentiation of short-lived plasmablasts to become long-lived plasma cells is impaired and the main contributor of antibody production are the short-lived plasmablasts. Overall, our data provides insights regarding the humoral memory persistence in recovered COVID-19 patients. Notwithstanding the insights from this study, it is still to be determined if the persistence of SARS-CoV-2 memory B cells can be considered as a correlate of protection in the absence of serological memory.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Frontiers in Immunology
based on 140 papers
Top 0.1%
20.5%
2
Clinical & Translational Immunology
based on 14 papers
Top 0.1%
6.1%
3
PLOS ONE
based on 1737 papers
Top 66%
5.5%
4
Viruses
based on 79 papers
Top 0.5%
4.9%
5
Scientific Reports
based on 701 papers
Top 40%
4.7%
6
PLOS Pathogens
based on 35 papers
Top 0.2%
2.9%
7
The Journal of Immunology
based on 19 papers
Top 0.5%
2.9%
8
Science Immunology
based on 15 papers
Top 0.2%
2.9%
50% of probability mass above
9
Cell Reports
based on 25 papers
Top 0.3%
2.6%
10
JCI Insight
based on 63 papers
Top 2%
2.5%
11
iScience
based on 74 papers
Top 2%
2.5%
12
Cell
based on 28 papers
Top 0.9%
2.4%
13
Journal of Medical Virology
based on 95 papers
Top 4%
2.4%
14
Nature Immunology
based on 14 papers
Top 0.7%
1.8%
15
Nature Communications
based on 483 papers
Top 28%
1.8%
16
Immunity
based on 11 papers
Top 0.5%
1.6%
17
Journal of Clinical Immunology
based on 11 papers
Top 0.3%
1.6%
18
Cell Reports Medicine
based on 49 papers
Top 3%
1.6%
19
Signal Transduction and Targeted Therapy
based on 10 papers
Top 0.4%
1.4%
20
Vaccines
based on 131 papers
Top 5%
1.2%
21
Journal of Clinical Investigation
based on 50 papers
Top 3%
1.2%
22
International Journal of Molecular Sciences
based on 39 papers
Top 3%
0.9%
23
mBio
based on 34 papers
Top 3%
0.8%
24
International Journal of Infectious Diseases
based on 115 papers
Top 19%
0.7%
25
Science Translational Medicine
based on 40 papers
Top 5%
0.7%
26
The Journal of Infectious Diseases
based on 137 papers
Top 11%
0.7%